Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer

SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease. The SAPPROC trial investigated the addition of the SRC inhibitor saracatinib (AZD05...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: McGivern, Niamh, El-Helali, Aya, Mullan, Paul, McNeish, Iain A., Paul Harkin, D., Kennedy, Richard D., McCabe, Nuala
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5797008/
https://ncbi.nlm.nih.gov/pubmed/29435137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23524
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki